BIO-Europe Spring EBD Group BIO BIO-Europe Spring

Thank you for participating in BIO-Europe Spring® 2014

Follow up, research and set notifications with watchlist > partnering360®
Download reports, stats and review your agenda > partneringONE®

BIO-Europe Spring® 2014 in numbers
  • 2,083 attendees
  • 10,780 one-to-one meetings
  • 2,115 licensing opportunities posted
  • 1,209 companies
  • 132 company presentations
  • 61 exhibitors
  • 42 countries represented
  • 17 workshops and panels

View impressions of BIO-Europe Spring ►
See videos of BIO-Europe Spring ►

Save the date and check back in the coming weeks for information on next year's BIO-Europe Spring, March 9–11, 2015 in Paris, France.

more ►

Conference videos

Interview with Matthias Krings, Catenion Interview with Matthias Krings, CatenionMarch 11, 2014 | BIO-Europe Spring® 2014Dr. Matthias Krings, Senior Partner at Catenion, speaks on challenges faced by medtech and some recent collaborations. Meet Krings in person at EuroMedtech 2014 in Linz this May. View session here View session here
Interview with John McDonald, Biogen Idec Interview with John McDonald, Biogen IdecMarch 11, 2014 | BIO-Europe Spring® 2014John F. McDonald of Biogen Idec answers the question, “How can a small company get Biogen Idec’s attention?” A must watch to prepare for your next round of partnering. View session here View session here
Interview with Mark Velleca, The Leukemia & Lymphoma Society Interview with Mark Velleca, The Leukemia & Lymphoma SocietyMarch 11, 2014 | BIO-Europe Spring® 2014Mark Velleca of The Leukemia & Lymphoma Society (LLS) wants new therapies now for life threatening hematological disease; LLS supports companies with promising treatments. View session here View session here
Interview with Sigal Weisswasser, The T.B.N. Group Interview with Sigal Weisswasser, The T.B.N. GroupMarch 11, 2014 | BIO-Europe Spring® 2014Sigal Weißwasser of The T.B.N. Group shares her approach to creating business acceleration strategies that span international boundaries in this interview ahead of EuroMedtech in May 2014. View session here View session here
Interview with Greg Scott, ChinaBio® LLC Interview with Greg Scott, ChinaBio® LLCMarch 11, 2014 | BIO-Europe Spring® 2014ChinaBio® Partnering Forum 2014 will be May 7–8 in Suzhou, China. Greg Scott, President of ChinaBio® LLC, discusses trends and strategies for companies doing business in China. View session here View session here
Interview with Richard Soll, WuXi AppTec Interview with Richard Soll, WuXi AppTecMarch 11, 2014 | BIO-Europe Spring® 2014Richard Soll discusses how WuXi AppTec can be your gateway to the China biotech market, helping companies gain the expertise to turn market access plans for China into action. View session here View session here
Interview with Mike Crowley, Genentech Interview with Mike Crowley, GenentechMarch 11, 2014 | BIO-Europe Spring® 2014Genetech has a significant footprint in immunology and an emerging infectious disease portfolio. Mike Crowley sheds light on his BD focus for increasing these lines of business. View session here View session here
Interview with Annastasiah Mudiwa Mhaka, Johns Hopkins Medicine Interview with Annastasiah Mudiwa Mhaka, Johns Hopkins MedicineMarch 11, 2014 | BIO-Europe Spring® 2014Annastasiah Mudiwa Mhaka with BD and Strategic Alliances at Johns Hopkins Medicine discusses their translational medicine strategy and some collaborative projects in the works. View session here View session here
Interview with Matthew Durdy, Cell Therapy Catapult Interview with Matthew Durdy, Cell Therapy CatapultMarch 11, 2014 | BIO-Europe Spring® 2014Matthew Durdy of Cell Therapy Catapult discusses the role of cell-based therapies in the next generation of healthcare, and strategies for their commercialization. View session here View session here
From pariah to darling: Biopharma finally courts immunotherapies From pariah to darling: Biopharma finally courts immunotherapiesMarch 10, 2014 | BIO-Europe Spring® 2014Immuno-oncology is suddenly the most talked about approach for changing the treatment paradigm of cancer, though not long ago almost no large biopharma wanted to touch these programs. View session here View session here
Gene therapy and gene modified cell therapies: What are the collaborative models and partnerships that will enable successful commercialization of these products?
Gene therapy and gene modified cell therapies: What are the collaborative models and partnerships that will enable successful commercialization of these products? March 10, 2014 | BIO-Europe Spring® 2014Gene therapy is fundamentally more complex than other biologics due to safety issues in developing and transporting a virus, but compelling clinical results make this worth solving. View session here View session here
The personalized therapy challenge: How can therapeutic developers incorporate a biomarker strategy that enhances rather than limits the commercial opportunity?
The personalized therapy challenge: How can therapeutic developers incorporate a biomarker strategy that enhances rather than limits the commercial opportunity? March 10, 2014 | BIO-Europe Spring® 2014A key question facing drug developers today is how to incorporate efficient use of biomarkers into a drug development program that will help validate a commercial opportunity. View session here View session here
Industry panel: Pharma steps up early on relevance data Industry panel: Pharma steps up early on relevance dataMarch 10, 2014 | BIO-Europe Spring® 2014Proof of Relevance (PoR) has now nearly displaced Proof of Concept (PoC) as the primary valuation driver for pharma buyers across discovery and development stages. View session here View session here
Go big or go home: When to go against the trends in R&D and dealmaking Go big or go home: When to go against the trends in R&D and dealmakingMarch 10, 2014 | BIO-Europe Spring® 2014Pharma companies boast about being innovation-driven, yet most of their R&D targets are the same. Pharma execs discuss why going into unpopular areas alone can be wildly successful. View session here View session here
Asset-centric companies: Still lean and mean or Asset-centric companies: Still lean and mean or "so 2012"? March 10, 2014 | BIO-Europe Spring® 2014Should biotechs be built to take advantage of a high-point or low-point in a cyclical market, or simply build in enough flexibility so companies are suited to any stage of the cycle? View session here View session here
Who will finance early stage drug discovery? Who will finance early stage drug discovery?March 10, 2014 | BIO-Europe Spring® 2014Financing data shows that private rounds for companies whose lead drug discovery programs are in preclinical development and earlier have been steadily rising since the meltdown. View session here View session here
Dealmaking strategies around orphan diseases Dealmaking strategies around orphan diseasesMarch 10, 2014 | BIO-Europe Spring® 2014What are the advantages/disadvantages of working with big pharma in rare diseases, and what can pharma bring to the table that biotechs in the orphan space would want to tap into? View session here View session here
Are big biotechs the better dealmakers? Are big biotechs the better dealmakers?March 10, 2014 | BIO-Europe Spring® 2014Between pharma and big biotech, which is the better dealmaker? Panelists weigh the pros and cons of partnering with each, and how to find the right strategic fit. View session here View session here
Interview with Rob Wills, Janssen Pharmaceuticals of Johnson & Johnson Interview with Rob Wills, Janssen Pharmaceuticals of Johnson & JohnsonMarch 11, 2013 | BIO-Europe Spring® 2013In this interview, Rob Wills shares his views on the state of innovation in the industry and tangible advice for biotechs trying to secure a pharma partnership. View session here View session here
Interview with Sander Slootweg, Forbion Capital Interview with Sander Slootweg, Forbion CapitalMarch 11, 2013 | BIO-Europe Spring® 2013Sander Slootweg of Forbion Capital discusses the different investment climates in Europe and the US, and how Forbion is helping portfolio companies navigate the changeable investment terrain. View session here View session here
Interview with Ed Mathers, NEA Interview with Ed Mathers, NEAMarch 11, 2013 | BIO-Europe Spring® 2013Is the industry suffering a crisis of innovation, or a crisis of investment? Ed Mathers of NEA shares his views on how to keep the engines of biotech running. View session here View session here
Cancer immunotherapies: Overcoming the key challenges to commercialization Cancer immunotherapies: Overcoming the key challenges to commercializationMarch 11, 2013 | BIO-Europe Spring® 2013How must cancer immunotherapy companies approach partnering in dealing with products that do not lend themselves to traditional partnering models? View session here View session here
Stem cells in drug discovery: New opportunities for biotech-pharma collaboration Stem cells in drug discovery: New opportunities for biotech-pharma collaborationMarch 11, 2013 | BIO-Europe Spring® 2013A new wave of drug discovery collaborations with industry and academia to use stem cell applications indicates pharma’s robust interest in stem cell biology. View session here View session here
Austerity for whom? Market access in Europe and its effect on dealmaking Austerity for whom? Market access in Europe and its effect on dealmakingMarch 11, 2013 | BIO-Europe Spring® 2013This panel explores both the current status and the outlook for cost-containment measures in Europe, and their implications for innovators and developers of new medicines. View session here View session here
Financing approaches to translate early stage innovation Financing approaches to translate early stage innovationMarch 11, 2013 | BIO-Europe Spring® 2013This panel discusses collaborative and business approaches to driving innovation and new paths to funding drug discovery and development. View session here View session here
How does pharma structure external R&D?  How does pharma structure external R&D? March 11, 2013 | BIO-Europe Spring® 2013Panelists review both early successes and lessons learned from the implementation of novel R&D and commercialization blueprints, and discuss what they could mean for the industry. View session here View session here
Going public: A review of recent IPOs Going public: A review of recent IPOsMarch 11, 2013 | BIO-Europe Spring® 2013Biotech has been a hot sector on Wall Street this past year, but there's no indication that we're on the verge of returning to the exuberant 1990s. View session here View session here
Examining major deals of the past year Examining major deals of the past yearMarch 11, 2013 | BIO-Europe Spring® 2013Dealmakers examine significant deals of the last 12 months, including transactions they have made, and what these deals reveal about pharma's priorities, strategy and options. View session here View session here
Exploring alternative financing models Exploring alternative financing modelsMarch 11, 2013 | BIO-Europe Spring® 2013With the shortage of classical VC investing and the boom in early opportunities and strong entrepreneurs, traditional VC is sharing the spotlight with alternative models. View session here View session here
Personalized oncology and next gen cancer drug development Personalized oncology and next gen cancer drug developmentMarch 11, 2013 | BIO-Europe Spring® 2013This session explores the impact of new technologies and novel therapeutic approaches to advance cancer drug development and deliver on the promise of personalized medicine. View session here View session here
Can’t live with you, can’t live without you: The VC and pharma relationship Can’t live with you, can’t live without you: The VC and pharma relationshipMarch 11, 2013 | BIO-Europe Spring® 2013If VCs don’t fund real innovation anymore and pharma is unable to innovate successfully, what does this trend portend and how can it be reversed? View session here View session here
Next generation anticancer approaches: Innovation meets commercial realities Next generation anticancer approaches: Innovation meets commercial realitiesMarch 20, 2012 | BIO-Europe Spring® 2012This discussion focuses on how commercial realities meet innovation within oncology, covering challenges companies face as oncology becomes increasingly competitive. View session here View session here
The assessment and management of assets: How to position the asset to attract a deal The assessment and management of assets: How to position the asset to attract a dealMarch 20, 2012 | BIO-Europe Spring® 2012There is still a great deal to learn about how to better position an asset to attract investors or deal partners, with an understanding of both short and long term goals. View session here View session here
Biotech business models for faster returns Biotech business models for faster returnsMarch 19, 2012 | BIO-Europe Spring® 2012Nimble entrepreneurs are developing funds and corporate structures that may once again make private biotech an attractive investment, focusing on the drug, not the company. View session here View session here
Close up and personal: Recent deals examined from both sides Close up and personal: Recent deals examined from both sidesMarch 19, 2012 | BIO-Europe Spring® 2012With special emphasis on Dutch biotech deals, executives discuss what the dealmaking hurdles were, what they learned from the process, and how the alliance has been managed View session here View session here
Regional focus: Leveraging commercial rights for emerging markets Regional focus: Leveraging commercial rights for emerging marketsMarch 19, 2012 | BIO-Europe Spring® 2012Life science companies are shifting focus to take advantage of specialty indications and regional markets, such as China, the Middle East, Russia and South America View session here View session here
Early stage financing: European and US VCs weigh in Early stage financing: European and US VCs weigh inMarch 19, 2012 | BIO-Europe Spring® 2012Is there a recipe for current VCs for successful investing in early stage science? Will recent initiatives from both government and industry help or hurt the venture industry? View session here View session here
Advanced therapies: Stem cell and immunotherapy promises in practice Advanced therapies: Stem cell and immunotherapy promises in practiceMarch 19, 2012 | BIO-Europe Spring® 2012This panel examines major clinical and commercial developments in using stem cells as drug discovery platforms, as well as the development of immunotherapies to treat cancer. View session here View session here
Unconventional deals to herculean strategies Unconventional deals to herculean strategiesMarch 19, 2012 | BIO-Europe Spring® 2012New realities in healthcare have caused investors to lean toward non-traditional dealmaking strategies. Panelists explore multifaceted, powerful, even herculean, strategies. View session here View session here
The opportunity of community drug development partnerships for personalized oncology and drug development The opportunity of community drug development partnerships for personalized oncology and drug developmentMarch 19, 2012 | BIO-Europe Spring® 2012Will community drug development partnerships among academic institutions, diagnostics companies, technology providers and bio/pharma lead to more effective cancer drugs? View session here View session here
Are orphan indications the only viable model for drug development? Are orphan indications the only viable model for drug development?March 19, 2012 | BIO-Europe Spring® 2012The opening plenary addresses orphan indications as a viable model for drug development. Panelists discuss development strategies and the future of personalized medicine. View session here View session here
Examining major deals of the past year Examining major deals of the past yearMarch 19, 2012 | BIO-Europe Spring® 2012Panelists examine significant deals of 2011, including what these deals reveal about pharma’s priorities, strategy and the options available to drug development companies. View session here View session here



About the BIO-Europe Spring® Conference

BIO-Europe Spring® 2013 Highlights

  • 2,071 attendees
  • 10,805 one-to-one meetings
  • 2,148 licensing opportunities posted
  • 1,219 companies
  • 136 company presentations
  • 56 exhibitors
  • 50 countries represented
  • 19 workshops and panels

Photos of BIO-Europe Spring 2013 ►

Where the global biotech industry comes to partner

BIO-Europe Spring® is the springtime counterpart to EBD Group’s flagship conference, BIO-Europe®, and continues the tradition of providing life science companies with high caliber partnering opportunities.

Featuring EBD Group’s sophisticated, web-based partnering system, partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

Who will you meet?

BIO-Europe Spring annually attracts top international executives from:

  • Established and emerging biotech companies
  • Pharmaceutical companies
  • Academic innovators
  • Private investors including venture capital and private equity
  • Companies developing companion diagnostics
  • Other industry related service companies

Breakdown of registrants and participating companies at BIO-Europe Spring

Previous Conferences ►

BIO-Europe Spring features

One-to-one meetings
One-to-one meetings
partneringONE® enables participants to identify and select potential partners. The system—industry-specific, web-based and interactive—is uniquely suited for the needs of life science companies. more

Sessions
Sessions
Panels and workshops feature corporate leaders who share insight, opinion and advice on how to navigate industry challenges. more

Company presentations
Company presentations
Select biotechnology, midsize and big pharmaceutical companies present their products and technologies and corporate strategies in 14-minute presentations. more

Exhibition
Exhibition
A lively exhibition in the heart of the conference area showcases companies, services and technologies. more

Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2014 EBD GmbH
Privacy Policy
Terms of Use
BIO-Europe Spring EBD Group BIO BIO-Europe Spring